AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33790870 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with bone turnover markers (CTX, P1NP, OC, sclerostin, OPG, RANKL) in T1D patients
Number of subjects: 190
Study 33790870 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with bone turnover markers (CTX, P1NP, OC, sclerostin, OPG, RANKL) in T2D patients
Number of subjects: 190
Study 33790901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-antivenom model
Number of subjects: 28
Study 33790901 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-antivenom model
Number of subjects: 28
Study 33791018 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PDN (19 patients)
Number of subjects: 39
Study 33791018 — intervention group
Group type: COMPARATOR
Intervention: Group NDN (20 patients)
Number of subjects: 39
Study 33791018 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (13 participants)
Number of subjects: 39
Study 33791217 — intervention group
Group type: EXPERIMENTAL
Intervention: HID-PBSCT using G-PB grafts
Number of subjects: 67
Study 33791217 — intervention group
Group type: COMPARATOR
Intervention: HID HSCT using the combination of G-BM and G-PB grafts
Number of subjects: 67
Study 33791343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa Flavanols
Number of subjects: 0
Study 33791343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33791349 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine oxygen therapy
Number of subjects: 0
Study 33791349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no routine oxygen therapy)
Number of subjects: 0
Study 33791897 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus blockade (BPB)
Number of subjects: 14
Study 33791920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pmsa (computerized algorithm)
Number of subjects: 18
Study 33791920 — intervention group
Group type: COMPARATOR
Intervention: Pms-Insp (interventional method)
Number of subjects: 18
Study 33792221 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapies targeting B-cell maturation antigen (BCMA)
Number of subjects: 0
Study 33792221 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapies targeting other antigens (SLAMF7 and CD44v6)
Number of subjects: 0
Study 33792221 — intervention group
Group type: COMPARATOR
Intervention: Current autologous CAR-T therapies
Number of subjects: 0
Study 33792222 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study 33792553 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch Series 4 paired with iPhone and RIFitTest app
Number of subjects: 25
Study 33792627 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric and nutrient restriction intervention
Number of subjects: 40
Study 33792627 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 40
Study 33792630 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and 10-day decitabine
Number of subjects: 97
Study 33792661 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite cardiac magnetic resonance (CMR)-based risk score
Number of subjects: 1008
Study 33792661 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite clinical and CMR-based risk score
Number of subjects: 1008
Study 33792661 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) evaluation
Number of subjects: 1008
Study 33792960 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-HDS/FGFR3 antibodies
Number of subjects: 322
Study 33793363 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACLR)
Number of subjects: 133
Study 33793651 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based proton density fat fraction (PDFF) using LMS-IDEAL
Number of subjects: 581
Study 33793651 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-derived controlled attenuation parameter (CAP)
Number of subjects: 581
Study 33794206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1
Number of subjects: 127
Study 33794206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib plus fulvestrant
Number of subjects: 127
Study 33794207 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2) and MRI-based adaptive brachytherapy (IGABT)
Number of subjects: 1341
Study 33794315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher C-reactive protein (CRP) polygenic risk score (PRS)
Number of subjects: 112171
Study 33794315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher C-reactive protein (CRP) PRS
Number of subjects: 112171
Study 33794315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TNF-α PRS
Number of subjects: 112171
Study 33794315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI PRS
Number of subjects: 112171
Study 33794440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus eribulin
Number of subjects: 44
Study 33794531 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 376
Study 33794531 — intervention group
Group type: EXPERIMENTAL
Intervention: History of allergy
Number of subjects: 376
Study 33794531 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory allergy
Number of subjects: 376
Study 33794531 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 60 years or more
Number of subjects: 376
Study 33794531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 376
Study 33794793 — intervention group
Group type: EXPERIMENTAL
Intervention: DACOLT study participants
Number of subjects: 600
Study 33794793 — intervention group
Group type: COMPARATOR
Intervention: Copenhagen General Population Study (CGPS) and Copenhagen City Heart Study (CCHS) controls
Number of subjects: 600
Study 33794832 — intervention group
Group type: EXPERIMENTAL
Intervention: SensiumVitals™ patch measuring temperature, heart & respiratory rates applied on arrival for the duration of stay.
Number of subjects: 14
Study 33794842 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomniac patients (ISI > 7)
Number of subjects: 28
Study 33794948 — intervention group
Group type: EXPERIMENTAL
Intervention: FES + VFBT (functional electrical stimulation with visual feedback balance training)
Number of subjects: 5
Study 33794977 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months exercise intervention
Number of subjects: 137
Study 33794977 — intervention group
Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 137
Study 33795193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine for high hENT1 (≥50%) group
Number of subjects: 44
Study 33795193 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus folinic acid (5-FU/FA) for low hENT1 (<50%) group
Number of subjects: 44
Study 33795193 — intervention group
Group type: COMPARATOR
Intervention: Control group (hENT1-independent adjuvant chemotherapy)
Number of subjects: 44
Study 33795208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagraxofusp and Azacitidine
Number of subjects: 0
Study 33795869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal sepofarsen injection
Number of subjects: 1
Study 33796143 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 504
Study 33796143 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 504
Study 33796147 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 40
Study 33796237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 33796237 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0
Study 33796237 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study 33796451 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 25
Study 33796452 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS + EG
Number of subjects: 1077
Study 33796452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-Bioscore
Number of subjects: 1077
Study 33796452 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Neo-Bioscore
Number of subjects: 1077
Study 33796452 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab therapy
Number of subjects: 1077
Study 33796452 — intervention group
Group type: COMPARATOR
Intervention: HER2-negative patients
Number of subjects: 1077
Study 33796490 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance of Acute SARS-CoV-2 Infections
Number of subjects: 0
Study 33797395 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Spot mental health app
Number of subjects: 0
Study 33797852 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis patients (n=50)
Number of subjects: 100
Study 33797852 — intervention group
Group type: COMPARATOR
Intervention: Non-periodontitis individuals (n=50)
Number of subjects: 100
Study 33798033 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth behavior change intervention for promoting physical activity and fruit and vegetable consumption
Number of subjects: 0
Study 33798209 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite profiling (measured 408 metabolites using mass spectrometry)
Number of subjects: 96
Study 33798209 — intervention group
Group type: COMPARATOR
Intervention: Control group (survivors who did not require transfer to the ICU)
Number of subjects: 96
Study 33798399 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy
Number of subjects: 0
Study 33798541 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 59
Study 33798541 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at bifurcation
Number of subjects: 59
Study 33798541 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at right hepatic duct
Number of subjects: 59
Study 33798541 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at common bile duct
Number of subjects: 59
Study 33798541 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at left hepatic duct
Number of subjects: 59
Study 33798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and ifosfamide for three neoadjuvant cycles plus concomitant hypofractionated radiotherapy (25 Gy in 5 fractions)
Number of subjects: 18
Study 33798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and ifosfamide plus hypofractionated RT
Number of subjects: 18
Study 33799685 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy) 50 mg/kg on days +3 and +4 combined with tacrolimus/mycophenolate mofetil (T/MMF) starting day +5
Number of subjects: 85
Study 33799685 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy) 50 mg/kg combined with T/MMF
Number of subjects: 85
Study 33799685 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy) + T/MMF
Number of subjects: 85
Study 33799966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell-derived exosomes
Number of subjects: 0
Study 33799966 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilators
Number of subjects: 0
Study 33800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (SRT) at 70 Gy in 35 fractions + locoregional deep hyperthermia (HT) (7-10 sessions)
Number of subjects: 52
Study 33800969 — intervention group
Group type: EXPERIMENTAL
Intervention: High Periodontal Index (HPI) group (PI > 22)
Number of subjects: 52
Study 33800969 — intervention group
Group type: COMPARATOR
Intervention: Low Periodontal Index (LPI) group (PI < 22)
Number of subjects: 52
Study 33801399 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin, administered every three weeks, median of four cycles (range: 1-40), mostly as a second-line treatment (~60% of patients)
Number of subjects: 512
Study 33801995 — intervention group
Group type: EXPERIMENTAL
Intervention: Macronutrient intakes in PCOS girls
Number of subjects: 59
Study 33802089 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate + Bevacizumab
Number of subjects: 48
Study 33802089 — intervention group
Group type: COMPARATOR
Intervention: Imatinib mesylate
Number of subjects: 48
Study 33802089 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 48
Study 33803049 — intervention group
Group type: EXPERIMENTAL
Intervention: solid ASD of efavirenz 50 mg
Number of subjects: 16
Study 33803049 — intervention group
Group type: EXPERIMENTAL
Intervention: dissolved ASD of efavirenz 50 mg
Number of subjects: 16
Study 33803049 — intervention group
Group type: COMPARATOR
Intervention: molecular solution of efavirenz 3 mg (non-ASD)
Number of subjects: 16
Study 33803366 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed to Emergency Department (ED)
Number of subjects: 1081
Study 33803366 — intervention group
Group type: COMPARATOR
Intervention: Directed to ED but not admitted to ICU
Number of subjects: 1081
Study 33803366 — intervention group
Group type: COMPARATOR
Intervention: Admitted to ICU within 7 days
Number of subjects: 1081
Study 33803366 — intervention group
Group type: COMPARATOR
Intervention: Transported by Mobile Intensive Care Unit (MICU) directly to ICU
Number of subjects: 1081
Study 33804500 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission Reduction Intervention Project (TRIP)
Number of subjects: 292
Study 33804657 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermographic imaging after local cooling of the hands for 1 min in water of 10°C
Number of subjects: 22
Study 33804657 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study 33804976 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-containing Eggshell Powder (ESP) supplementation, 2.4 g daily for 6 months
Number of subjects: 82
Study 33804976 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 82
Study 33804976 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-containing Eggshell Powder (ESP) supplementation
Number of subjects: 82
Study 33804999 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 200
Study 33804999 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 200
Study 33805367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 3000
Study 33805367 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 3000
Study 33805367 — intervention group
Group type: COMPARATOR
Intervention: Full axillary lymph node dissection (ALND)
Number of subjects: 3000
Study 33805731 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT) including radiotherapy with concurrent 5-Fluorouracil (5-FU)/Capecitabine and Oxaliplatin.
Number of subjects: 111
Study 33805731 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT).
Number of subjects: 111
Study 33805793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m²
Number of subjects: 0
Study 33806653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessment in juvenile athletes who were donor twins
Number of subjects: 0
Study 33806653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessment in juvenile athletes who were recipient twins
Number of subjects: 0
Study 33807097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent oral vaccine against enteric fever, specific dosage and duration not mentioned.
Number of subjects: 0
Study 33807097 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details on control treatment not available.
Number of subjects: 0
Study 33808348 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaires assessing pain, quality of life, and catastrophizing.
Number of subjects: 0
Study 33808348 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of bone turnover biomarkers and inflammatory cytokines in fasting serum samples.
Number of subjects: 0
Study 33808348 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of bone innervation in diagnostic biopsies.
Number of subjects: 0
Study 33808371 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental stress (measured using the Parental Stress Index)
Number of subjects: 250
Study 33808883 — intervention group
Group type: COMPARATOR
Intervention: Total body adiposity indices (BMI, CUN-BAE, Deurenberg's formula) and abdominal adiposity (waist and neck circumferences, conicity index, waist to height ratio, Bonora's equation, A body shape index, body roundness index)
Number of subjects: 8188
Study 33809385 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoBEO (nanotechnology delivery system of bergamot essential oil deprived of furocumarins)
Number of subjects: 0
Study 33809385 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot essential oil (BEO)
Number of subjects: 0
Study 33809385 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33809538 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone (LH) and human chorionic gonadotropin (hCG)
Number of subjects: 591
Study 33809538 — intervention group
Group type: EXPERIMENTAL
Intervention: sLHCGR
Number of subjects: 591
Study 33809705 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ and low iron stores (inflammation-unadjusted serum ferritin ≤ 40 µg/L)
Number of subjects: 0
Study 33809705 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study 33810313 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 33810313 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 0
Study 33810313 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 0
Study 33810795 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 116
Study 33810795 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 116
Study 33811142 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical imbalance mapping (AIM)
Number of subjects: 0
Study 33811142 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical imbalance change
Number of subjects: 0
Study 33811142 — intervention group
Group type: EXPERIMENTAL
Intervention: Interindividual variation in whole-brain average anatomical imbalance
Number of subjects: 0
Study 33811164 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine skin cancer screening and education about skin self-exams (NCI cases)
Number of subjects: 293
Study 33811182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition ultrasound imaging before the brachial plexus block
Number of subjects: 100
Study 33811182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition ultrasound imaging after the brachial plexus block
Number of subjects: 100
Study 33811182 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition ultrasound imaging at the lateral infraclavicular fossa after the brachial plexus block
Number of subjects: 100
Study 33811291 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-Image guided RAPN (3D-IGRAPN)
Number of subjects: 157
Study 33811356 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (GLE/PIB)
Number of subjects: 80
Study 33811727 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 800 mg/m²
Number of subjects: 0
Study 33811727 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 33812378 — intervention group
Group type: EXPERIMENTAL
Intervention: Age associations with lipid species
Number of subjects: 980
Study 33812378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex associations with lipid species
Number of subjects: 980
Study 33812378 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related associations by sex
Number of subjects: 980
Study 33812378 — intervention group
Group type: EXPERIMENTAL
Intervention: Age*sex interaction effects
Number of subjects: 980
Study 33812381 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 17
Study 33812381 — intervention group
Group type: COMPARATOR
Intervention: Conventional HIV testing
Number of subjects: 17
Study 33812665 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult tracheal intubation (defined as two failed attempts of direct laryngoscopy)
Number of subjects: 4683
Study 33812665 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult tracheal intubation
Number of subjects: 4683
Study 33812668 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthesia for surgical or diagnostic procedures
Number of subjects: 5609
Study 33812913 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose escalation with simultaneous integrated boost (SIB) technique, delivering 62.5-64 Gy/25-32 fractions to GTV, with SIB up to 70 Gy for pre-treatment 50% SUVmax area of GTV, plus 2 cycles of chemotherapy (cisplatin and fluorouracil) concurrently and 2 more cycles after radiotherapy.
Number of subjects: 44
Study 33812913 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose escalation with SIB (Level 3&4)
Number of subjects: 44
Study 33812913 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal dose of the esophagus (Dmax)
Number of subjects: 44
Study 33813233 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-item Insomnia Severity Index (ISI-2)
Number of subjects: 280
Study 33813517 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG/hMG
Number of subjects: 41
Study 33813517 — intervention group
Group type: COMPARATOR
Intervention: GnRH pump
Number of subjects: 41
Study 33813521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative CM recordings from CI electrode contact during insertion with a 0.5 kHz tone burst stimulus.
Number of subjects: 14
Study 33813521 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinsertion CM recordings from odd-numbered electrode contacts (1-15) using a range of stimulus frequencies (0.125 to 2 kHz).
Number of subjects: 14